series-c-plus
Stage
1
Investors
About
Volition develops blood-based diagnostic tests using epigenetic nucleosome quantification technology for the early detection and monitoring of diseases including cancer, sepsis, and NETosis, serving both human and veterinary medicine.
Explore Volition's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.